06.05.25 -- Why Better Manufacturing Is The Key To Unlocking Cell Therapy's Full Potential

This chapter discusses basics of gene therapies, including function, anticipated growth rates, companies involved and estimates of therapies in pipeline, and examples of commercial products and indications.

Perfusion cell culture technology supports high cell densities and product yields for viral vaccine manufacturing, offering a reliable way to produce high-quality cells at a commercial scale.

Review studies that showcase the potential of the CHOgro Expression System in early stage drug development, where high titer antibody production in suspension CHO cells is crucial.

While most hcDNA molecules outside AAV particles can be eliminated during downstream processing, encapsidated hcDNA molecules remain largely undetectable. Learn how to overcome this critical issue.

The demand for viral vectors continues to grow, making addressing the challenges related to their manufacturing and scale-up increasingly critical.

The industry is shifting from traditional processes to take advantage of single-use technology benefits. Discover how you can bypass traditional biomanufacturing and disposable multilayered films.

Consider a fully automated, closed counterflow centrifuge system for your monocyte-derived immunotherapies manufacturing. 

Learn about a solution that can provide a simple, easy, and versatile method for capsule and depth filtration, allowing a quick, efficient move from cell harvest to purification.

Read how the incorporation of transfer sets designed to support CGTs will aid in the implementation of controllable, consistent, and safe cGMP amenable manufacturing procedures.

Robotic aseptic fill finish equipment offers many benefits to modern facilities, including flexibility to adjust to future growth and the speed to market necessary for today’s changing industry.